Aspen Neuroscience secured $115 million in Series C financing to support its personalized autologous cell therapy program for Parkinson’s disease and to expand manufacturing capacity. The funding will back an ongoing clinical trial and preparations for a planned Phase 3 start, while shoring up GMP capabilities for scaled autologous production. Aspen’s approach centers on autologous regenerative therapies developed from patient‑derived cells; management indicated the new capital shortens timelines to pivotal studies and strengthens the company’s balance sheet ahead of a potential IPO in 2026. The raise included participation from strategic and financial investors. Investors and corporate partners will monitor clinical readouts and manufacturing cost profiles closely—autologous cell therapies remain capital‑intensive and dependent on streamlined production to achieve commercial viability.